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Introduction
Adult-onset Still’s disease (AOSD) is a rare auto-inflam-
matory disorder resembling a similar pediatric syndrome
known as systemic juvenile idiopathic arthritis (SJIA).[1]
The superimposable systemic and clinical features in
SJIA and AOSD suggest that both clinical phenotypes
represent a disease continuum with a pediatric (SJIA)
and more adult-onset (AOSD).[2] Analyses of gene
expression profiles may be useful not only for disease
classification, diagnosis, and prognosis, but also to iden-
tify disease specific treatment effects that counteract the
underlying pathological mechanisms. Here, we address
the question: How do genes that respond to canakinu-
mab treatment in SJIA patients[3] behave in AOSD
patients with active disease relative to healthy controls
and prior to IL-1 targeting therapy?
Objectives
To determine how genes that respond to IL-1b blockade
with canakinumab in SJIA patients behave in AOSD
patients relative to healthy controls.
Patients and methods
SJIA gene expression profiles pre- and post canakinumab
treatment were compared with AOSD patients relative to
healthy subjects using Affymetrix U133Plus2 DNA
microarrays.
Results
Consistently, all genes down-regulated in SJIA following
canakinumab treatment were upregulated in a majority
of AOSD patients with active disease relative to healthy
subjects and prior to canakinumab treatment. A few of
the AOSD patients resembled healthy subjects. Compar-
ison of the gene expression patterns to neutrophil
counts suggested that elevated neutrophil numbers were
closely correlated to the up-regulation of IL-1 associated
gene expression.
Conclusions
Results are consistent with and further support the con-
cept of a Still’s disease continuum that presents as pedia-
tric/juvenile SJIA or adult-onset Still’s disease. Moreover,
they suggest that AOSD is an IL-1 driven condition that
is also mechanistically similar to SJIA and that the
observed canakinumab response signature is likely to
show a comparable treatment response to IL-1b blockade
in AOSD.
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